Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: A retrospective database study

Drug, Healthcare and Patient Safety

Volumn 5, Issue 1, 2013, Pages 143-150

  Sato, Izumi ^a   Akazawa, Manabu ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Adverse drug reaction; Antihypertensive; Elderly; Pharmacoepidemiology; Polypharmacy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADVERSE DRUG REACTION; AGE; AGED; ANTIHYPERTENSIVE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; GENDER; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 84879471833     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S45347     Document Type: Review

References (45)

1. World Health Organization Media Centre [homepage on the Internet]. Medicines: rational use of medicines [Fact sheet N1338, May 2010]. Geneva: World Health Organization; 2010. Available from: http://www.who.int/mediacentre/factsheets/fs338/en/index.html. Accessed April 27, 2013.
2. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123-132.
3. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2008;85(1):86-88.
4. Aparasu RR, Mort JR, Brandt H. Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. Res Social Adm Pharm. 2005;1(3):446-459.
5. Lee RD. Polypharmacy: a case report and new protocol for management. J Am Board Fam Pract. 1998;11(2):140-144.
6. Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer-Ruskamp FM. Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol. 1999;55(7):533-536.
7. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36-41.
8. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113-121.
9. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-351.
10. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6(6):695-704.
11. Ministry of Health, Labour and Welfare. [homepage on the Internet, in Japanese]. Patient Survey 2008. Tokyo: Ministry of Health, Labour and Welfare; 2008 [cited December 3, 2009]. Available from: http://www.mhlw.go.jp/toukei/saikin/hw/kanja/08/index.html. Accessed April 27, 2013.
12. Suzuki Y, Akishita M, Arai H, Teramoto S, Morimoto S, Toba K. Multiple consultations and polypharmacy of patients attending geriatric outpatient units of university hospitals. Geriatr Gerontol Int. 2006;6(4):244-247.
13. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
14. Reid JL. Fall and rise of polypharmacy. Hypertension. 2007;49(2): 266-267.
15. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77(9):1279-1286.
16. Matsuoka H. Large clinical trials of ARB in Japan and its reflection to new guidelines. Nihon Rinsho. 2009;67(4):669-674. Japanese.
17. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther. 2000;14(3):295-301.
18. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516-1523.
19. Cooney D, Pascuzzi K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin Geriatr Med. 2009;25(2): 221-233.
20. Arai H, Akihita M, Teramoto S, et al. Incidence of adverse drug reactions in geriatric units of university hospitals. Geriatr Gerntlo Int. 2005;5(4):293-297.
21. Akishita M, Toba K, Nagano K, Ouchi Y. Adverse drug reactions in older people with dementia. J Am Geriatr Soc. 2002;50(2):400-401.
22. Tanaka K, Morita Y, Kawabe E, Kubota K. Drug use investigation (DUI) and prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf. 2001;10(7):653-658.
23. Kubota K, Koyama H. Pharmacovigilance and Risk Management in Japan. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester, UK: John Wiley and Sons, Ltd; 2007:387-394.
24. Matsushita Y, Sugihara M, Kawasugi K. Integration of Drug Use-Results Survey (DUS) Data of a Pharmaceutical Manufacturer. Jpn J Pharmacoepidemiol. 2010;15(2):61-71.
25. Risk/Benefit Assessment of Drugs-Analysis and Response Council. Database for Drug Use-Results Survey, Antihypertensives/Antibacterial agents. Available from: http://www.rad-ar.or.jp/01/05_datebase/kitei/form/DB_DURS_leaflet.pdf. Accessed April 27, 2013.
26. Fujita T, Miura Y, Mayama T. A pilot study to build a database on seven anti-hypertensive drugs. Pharmacoepidemiol Drug Saf. 2005;14(1):41-46.
27. Centers for Disease Control and Prevention [webpage on the Internet]. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Atlanta: Centers for Disease Control and Prevention [updated October 4, 2012]. Available from: http://www.cdc.gov/nchs/icd/icd9 cm.htm. Accessed April 27, 2013.
28. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization [homepage on the Internet]. MedDRA-the Medical Dictionary for Regulatory Activities [updated March 1, 2013]. Available from: http://www.meddramsso.com/index.asp. Accessed April 27, 2013.
29. Yokotsuka M, Aoyama M, Kubota K. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM). Int J Med Inform. 2000;57(2-3): 139-153.
30. Ministry of Health, Labour and Welfare. Drug Classification Codes for Internal Medicines. Tokyo: Ministry of Health, Labour and Welfare; 2013 [updated April 16, 2013]. Available from: http://www.mhlw.go.jp/topics/2012/03/dl/tp130418-01_1.pdf. Accessed April 27, 2013.
31. Fujita T, Mayama T. [A database of anti-hypertensive drugs from Drug Use Investigations and its practical use example]. Japan Statistical Society. 2007;36(2):205-217. Japanese [with English abstract].
32. Yoshida M, Matsumoto T, Suzuki T, Kitamura S, Mayama T. Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiol Drug Saf. 2008;17(1):70-75.
33. Ishiguro C, Fujita T, Omori T, Fujii Y, Mayama T, Sato T. Assessing the effects of non-steroidal anti-inflammatory drugs on antihypertensive drug therapy using post-marketing surveillance database. J Epidemiol. 2008;18(3):119-124.
34. Risk/Benefit Assessment of Drugs-Analysis and Response Council. PE/SOP2 Administrative Rules and Regulations of Database for Drug Use-Result Surveys [cited June 2011]. Available from: http://www.rad-ar.or.jp/01/05_datebase/kitei/form/PE_DB_kanri20110628en.pdf. Accessed April 27, 2013.
35. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235.
36. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006;15(7):444-453.
37. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003;20(11):817-832.
38. Maeda K. Systematic review of the effects of improvement of prescription to reduce the number of medications in the elderly with Polypharmacy. Yakugaku Zasshi. 2009;129(5):631-645.
39. Fillit HM, Futterman R, Orland BI, et al. Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. Am J Manag Care. 1999;5(5):587-594.
40. Muir AJ, Sanders LL, Wilkinson WE, Schmader K. Reducing medication regimen complexity: a controlled trial. J Gen Intern Med. 2001;16(2):77-82.
41. Fick DM, Maclean JR, Rodriguez NA, et al. A randomized study to decrease the use of potentially inappropriate medications among community-dwelling older adults in a southeastern managed care organization. Am J Manag Care. 2004;10(11 Pt 1):761-768.
42. Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med. 2004;116(6):394-401.
43. Ministry of Health, Labour and Welfare. Health Policy Publication 0430-1. Tokyo: Ministry of Health, Labour and Welfare; 2010 [cited April 30, 2010]. Available from: http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/T100506G0010.pdf. Accessed April 27, 2013.
44. Yamamura S, Yamamoto N, Oide S, Kitazawa S. Current state of community pharmacy in Japan: practice, research, and future opportunities or challenges. Ann Pharmacother. 2006;40(11):2008-2014.
45. Watanabe S, Nakano Y, Nomura K. [Steps in developing a database of drug use-result surveillance: as an example of anti-hyperlipidemia drugs]. Jpn J Pharmacoepidemiol. 2012;17(2):87-97. Japanese [with English abstract].